Erytech Pharma S.A. (ERYP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ERYP Stock Summary
- ERYP has a market capitalization of $46,506,122 -- more than approximately only 8.27% of US stocks.
- In terms of volatility of its share price, ERYP is more volatile than 97.19% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ERYP comes in at -123.75% -- higher than that of only 2.95% of stocks in our set.
- Stocks that are quantitatively similar to ERYP, based on their financial statements, market capitalization, and price volatility, are ORGS, IVA, GOVX, CBIO, and VCNX.
- ERYP's SEC filings can be seen here. And to visit Erytech Pharma SA's official web site, go to www.erytech.com.
ERYP Stock Price Chart Interactive Chart >
ERYP Price/Volume Stats
| Current price | $1.10 | 52-week high | $9.50 |
| Prev. close | $1.12 | 52-week low | $0.98 |
| Day low | $1.04 | Volume | 4,188 |
| Day high | $1.10 | Avg. volume | 488,667 |
| 50-day MA | $1.20 | Dividend yield | N/A |
| 200-day MA | $2.40 | Market Cap | 34.12M |
Erytech Pharma S.A. (ERYP) Company Bio
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
Latest ERYP News From Around the Web
Below are the latest news stories about Erytech Pharma SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
Erytech Shares Gain After Expanding Patent Portfolio For Treatment Of Rare Metabolic DiseasesErytech Pharma Plc (NASDAQ: ERYP) received a US patent covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D). The claims will also cover methods of treating other indications, including arginine-dependent cancers, septic shock, and angiogenesis-associated diseases. Erytech's red blood cell-encapsulated therapeutics can be deployed to reduce pathological levels of various metabolites in certain inborn errors of metabolism disorders. E |
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic DiseasesERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Cambridge, MA (U.S.) and Lyon (France), February 8, 2022 – ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficien |
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2022Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
Erytech reports results of two eryaspase trials in pancreatic cancer at ASCO GI 2022ERYTECH Pharma (ERYP) announces presentation of results of two clinical trials of eryaspase in pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal |
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
ERYP Price Returns
| 1-mo | -4.35% |
| 3-mo | -38.89% |
| 6-mo | -53.19% |
| 1-year | -76.79% |
| 3-year | -84.29% |
| 5-year | N/A |
| YTD | -53.19% |
| 2021 | -74.54% |
| 2020 | 25.15% |
| 2019 | 8.94% |
| 2018 | -69.26% |
| 2017 | N/A |
Continue Researching ERYP
Want to see what other sources are saying about Erytech Pharma SA's financials and stock price? Try the links below:Erytech Pharma SA (ERYP) Stock Price | Nasdaq
Erytech Pharma SA (ERYP) Stock Quote, History and News - Yahoo Finance
Erytech Pharma SA (ERYP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...